FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
7 letters match. Newest first.
-
DrugsHubei Gedian Humanwell Pharmaceutical Co., Ltd.
FDA: Hubei Gedian Humanwell API plant has scratched, stained equipment and weak quality unit oversight.
High risk -
DrugsHikal Limited
FDA warned India's Hikal Limited that unresolved metal-particle complaints in its APIs and weak supplier oversight make its active ingredients adulterated.
High risk -
DrugsTyche Industries Ltd
FDA warned Tyche Industries over falsified records, dirty equipment, and untested raw materials at its API plant.
High risk -
DrugsJagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals cited for API CGMP and listing failures after Indian inspection, leading to US import alert.
High risk -
DrugsWuhu Nuowei Chemistry Co., Ltd.
FDA cited Wuhu Nuowei Chemistry for API CGMP deviations in impurity testing, stability data, and cleaning, and placed products on import alert.
High risk -
DrugsZhejiang Tianyu Pharmaceutical Co., Ltd.
Zhejiang Tianyu Pharmaceutical made active pharmaceutical ingredients (API) with current good manufacturing practice (CGMP) deviations in impurity investigations and equipment cleaning.
High risk -
DrugsJost Chemical Co.
Jost Chemical Co. made active drug ingredients under CGMP deviations, including mold contamination and inadequate investigations.
High risk